doctor

Professor Chen Tao is an internationally renowned expert in cancer immunotherapy and currently serves as the Director of the International Medical Center at Guangzhou Fosun Chancheng Hospital. His distinguished academic career spans top medical institutions in both China and the United States. He studied under the tutelage of Academician Lu Daopei, a leading authority in hematology in China, and completed systematic research and clinical training at the Institute of Hematology, Peking University. He then pursued advanced studies at Massachusetts General Hospital, Harvard University, a world-renowned medical institution, where he completed postdoctoral research and remained on staff. During his tenure, he co-founded the Vaccine and Immunotherapy Research Center at Massachusetts General Hospital, Harvard University, with the renowned scholar Professor Mark Poznansky, leading pioneering research and translational applications in immunotherapy for cancer and clinical diseases. Professor Chen not only possesses a profound research background but has also passed the United States Medical Licensing Examination (USMLE), obtaining clinical practice qualifications and achieving exceptional integration from basic research to clinical application.

With over four decades of extensive experience dedicated to the field of tumor immunology, Professor Chen was awarded the Leukemia Research Outstanding Contribution Award during his time in the United States and holds international patent authorization. His academic influence is widely recognized internationally, and he is frequently invited to deliver keynote speeches at top-tier academic conferences. He also serves as a reviewer for several prestigious international medical journals.

Professor Chen Tao specializes in the precise diagnosis and comprehensive treatment of hematological malignancies (such as leukemia, lymphoma, and multiple myeloma) and various solid tumors, with particular expertise in the following areas:

Cancer Immunotherapy: Proficient in the personalized application of advanced immunotherapies, including cellular immunotherapy, immune checkpoint inhibitors, and therapeutic cancer vaccines.

Multimodal Integrated Therapy: Skilled in innovatively integrating immunotherapy with traditional approaches such as chemotherapy, targeted therapy, and radiotherapy, developing optimal sequential or combination treatment plans for patients.

Management of Complex and Severe Cases: Specializes in treating relapsed or refractory hematological lymphomas and metastatic solid tumors, providing internationally aligned treatment solutions.

Precise Immune Function Assessment: Utilizes advanced testing systems to comprehensively evaluate patients' immune status, establishing a scientific foundation for precise immunotherapy.

Advisor, Tumor Immunotherapy Professional Committee, Guangdong Clinical Medical Association

Committee Member, Clinical Chemotherapy Professional Committee, Chinese Anti-Cancer Association

Committee Member, Translational Medicine in Hematology Professional Committee, Chinese Anti-Cancer Association

Vice Chairman, Tumor Prevention and Rehabilitation Professional Committee, Guangdong Health Care Association

Vice Chairman, Lymphoma Prevention and Control Professional Committee, Fujian Preventive Medicine Association